Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

AstraZeneca is raising its defenses against Johnson & Johnson in a fierce competition in EGFR-mutated non-small cell lung cancer. | Following an FDA approval last year based on a tumor progression ...

AstraZeneca Plc. announced on Monday that it plans to invest $50 billion in the U.S. by 2030, with a focus on expanding drug ...

AstraZeneca said it is investing $50 billion in US manufacturing by 2030, following the lead of big pharma peers that have ...

AstraZeneca’s (AZN) Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer, or NSCLC ...